A new study suggests the introduction of personalized thresholds for diagnosing hypertrophic cardiomyopathy (HCM) in proposals that challenge long-standing one-size-fits-all diagnostic standards.
A new study suggests that patients assigned to finerenone are more likely to experience an initial decline in estimated glomerular filtration rate (eGFR) between randomization and one month compared to placebo.
Findings from a recent review have shed further light on the financial burden of heart failure medications on patients, as well as the systemic barriers that hinder cost-effective treatment.
No sex-specific differences are noted in the effectiveness and safety of two doses of aspirin for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) events, a secondary analysis of the ADAPTABLE trial shows.
Medicare patients are not at greater risk for cardiovascular disease (CVD) when taking anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for migraines, compared with onabotulinumtoxinA treatment, shows a cohort study.
Low-risk, trial-like patients undergoing SAVR during the trial enrollment period have similar 30-day rates of mortality, but lower rates of stroke, compared with patients in the SAVR arm of the PARTNER 3 and Evolut Low Risk trials, a cross-sectional analysis shows.
Incident hypertension and hypertension-related outcomes can be predicted by an artificial intelligence-enhanced electrocardiography (AI-ECG) model, AI-ECG risk estimator to predict incident hypertension, results from a cohort study show.
Redo transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 (S3) valve presents challenges, according to a new analysis of patient data that also shows downsizing is frequent, and under-expansion may lead to suboptimal hemodynamics.
New study findings challenge established practices in transcatheter aortic valve replacement (TAVR), as researchers demonstrate that transradial secondary access (TR-SA) significantly reduces complications compared to traditional transfemoral secondary access (TF-SA).
A first-in-human study has demonstrated the exceptional safety and efficacy of the Magenta Elevate mechanical circulatory support (MCS) device during high-risk percutaneous coronary interventions (HR-PCI) involving the left main coronary artery (LM).
Natalie Morrison, CRTonline.org
Bailey G. Salimes, CRTonline.org
Will Chu, CRTonline.org
Nathan Gray, CRTonline.org
Michael Mahmoudi, MD - K Goel, et al.; Circulation 2024; 150:1493-1504
Michael Mahmoudi, MD - N Singh, et al.; JACC Cardiovasc Interv 2024; 17:2337-2349
Michael Mahmoudi, MD - P Ridker, et al.; NEJM 2024; 391:2087-2097
Michael Mahmoudi, MD - R Hahn, et al. NEJM 2024 Online
Which of the following trials presented in 2024 will have the greatest impact on your practice?
DANGER SHOCK
TRISCEND II TRIAL
ECLIPSE
CLEAR SYNERGY OASIS 9
EARLY TAVR
SMART
RESHAPE-HF2 Trial
PREVENT
ORBITA-COSMIC
Mohit Pahuja, Kalyan R. Chitturi, Aakash Tuli, Abhinav Saxena, Adam Johnson, Akhil S. Kallur, Cheng Zhang, Hank Rappaport, Corey Shea, Jason P. Wermers, Hayder D. Hashim, Nelson L. Bernardo, Lowell F. Satler, Itsik Ben-Dor, Samer S. Najjar, Farooq H. Sheikh and Ron Waksman
Francesco Gallo, Matteo D'Addazio, Gianpiero D'Amico, Domenico G. Della Rocca, Patrizio Mazzone, Stefano Bordignon, Gavino Casu, Francesco Giannini, Sergio Berti, Rodney P. Horton, Giuseppe D'Angelo, Lukas Urbanek, Pierluigi Merella, Rossella Ruggiero, Francesco Bosica, Boris Schmidt, Enrico Atzori, Marco Barbierato, Andrea Natale, Sakis Themistoclakis and Federico Ronco
Ricardo Fonseca Oliveira Suruagy Motta and Anderson Matheus Pereira da Silva
Usama Qamar, Maaz Asif, Waleed Qamar and Siddharth Agarwal
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details